Modular virtual reality therapeutic for opioid and stimulant use disorders

Ended Project Grant Awarded Last action

Award ID
R44DA059475
Recipient
Awarding agency
Obligated
$1,291,358

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date
Originally
Place of performance
Michigan, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Opioid and/or stimulant use disorders (OUD/stud) are chronic, recurring conditions that if left untreated, pose a significant and ongoing public health and safety threat, with costs associated with OUD alone in the US exceeding one trillion dollars annually. Virtual reality CUE exposure (vrce) employs safe and controlled repeated exposure to a variety of substance use cues and environments designed to induce craving within the virtual space. This can be done in a way that is not feasible "in vivo" due to health and safety concerns, filling a persistent GAP in current treatment approaches for the non-pharmacological treatment of OUD/stud. While in the virtual environment, the patient will habituate to the substance use cues and work with a therapist to learn coping skills for tolerating craving while not ingesting substances, weakening the conditioned association between substance use cues and actual substance use. The helixvr digital therapeutic is a modular vrce based software that allows for simulations to be tailored to each patient and is designed for use as an adjunctive treatment for OUD/stud under the supervision of a licensed master's level behavioral health provider. Phase i work to be completed will include refinement of the user interface and increasing the number of features offered within the software. In phase i we will conduct a pilot effectiveness study to investigate the impact of helixvr on substance craving, substance use and overall quality of life. Participants (n = 50) will be randomized to receive 4 sessions of helixvr or another active VR based intervention at an outpatient substance use treatment organization. Our phase i hypothesis is that the addition of the fully immersive and tailored helixvr intervention into routine treatment will be associated with increased treatment completion, decreased substance craving and decreased substance use relative to a non-tailored less immersive VR intervention. This work will be followed by a phase II study to expand the number of cues and environments available while conducting a muti-site RCT (n = 200) to further evaluate the effectiveness of helixvr. Our phase II hypothesis is that the use of the helixvr digital therapeutic will result in decreased craving and substance use, as well as decreased return to use, emergency healthcare usage, involvement with child welfare and involvement with the criminal justice system. We anticipate that these changes will be maintained for 12 months post treatment. We will continuously adjust our business plan, software content and clinical workflow integration protocols based on feedback from our target customer demographics. Our long-term goal is to offer a high impact digital therapeutic which is easily integrated into clinicians' normal workflow, decreasing the significant social and public health impact of OUD/stud.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $6,500
Amendment $6,500
Amendment $1,642
Amendment $1,642
Amendment $1,642
Amendment $318,358
Amendment $318,358
Amendment $318,358
Original award $318,358
Show all 11

Quick answers

Who received award R44DA059475?

R44DA059475 was awarded to Innatevr LLC by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2023.

How much is award R44DA059475 worth?

$1,291,358 has been obligated on R44DA059475.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login